QuarterHawkSign in

China Pharma Holdings, Inc. (CPHI)

Healthcare

No action
Fundamental
1
Sentiment
1
Technical
4

Do Nothing: fundamentalScore 1 and qualitativeScore 1 are both below the required floor of 3; despite a technically strong breakout, the strategy suppresses fresh longs and the stop window also showed a 7.27% overnight gap.

Analysis as of 2026-07-17· about 2 trading days ago

Company overview

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceuticals and biochemical products. The company serves hospitals and independent retailers in mainland China, offering a range of formulations including injectables, tablets, and capsules. Its products address various health conditions such as neurological, cardiovascular, and infectious diseases.

Fundamental

very weak
Fundamental1
Severe distress

Liquidity and going-concern risks dominate, with negative margins and declining revenue.

FundamentalScore 1/5: SEC filings explicitly disclose substantial doubt about going concern, with cash only about $0.17M (latest 10-Q) and a ~$5.3M working-capital deficit. The business is deeply unprofitable (TTM gross margin -13.42%, net margin -88.82%) and revenue has shrunk (~-19.06% 2021–2025 CAGR). Discounted-cash-flow outputs are negative, making the stock highly speculative.

Sentiment

very weak
Sentiment1
Speculative attention

Media and retail focus on volume spikes, overshadowed by going-concern disclosures.

Tape-driven momentum around unusual-volume moves (technical catalyst is rumored) with the company stating it knows of no undisclosed events; baseline sentiment delta is indeterminate due to sparse/noisy prior coverage. Severe red-flag: recent going-concern/substantial-doubt disclosure (per filings noted upstream) caps the score at 1.

Technical

good
Technical4
Extended breakout

Strong trend and momentum indicators, but volatility and risk are high.

Trend and momentum are strong: the input snapshot sits above SMA20, SMA50, SMA200, EMA9, EMA21, and the latest daily VWAP, while MACD is positive and above signal and ADX is elevated at 50.19. The weak points are RSI14 at 77.01 and ATR14 at 15.50% of price, which mark the move as extended and highly volatile rather than cleanly buyable.

You’re looking at 2026-07-17 — about 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.